Results 171 to 180 of about 410,735 (351)

The Potential of Phytochemicals to Overcome Multidrug Resistance in Metastatic Melanoma

open access: yesChemistry &Biodiversity, EarlyView.
ABSTRACT Metastatic melanoma is the most lethal form of skin cancer, accounting for most skin cancer‐related deaths. Immunotherapies and targeted therapies have improved overall and progression‐free survival rates in metastatic melanoma patients. The effectiveness of these therapies decreases due to multidrug resistance (MDR).
Jacqueline Maphutha   +4 more
wiley   +1 more source

Epidemiology of fungal urinary tract infections: A retrospective case series. [PDF]

open access: yesNew Microbes New Infect
Khateb AM   +4 more
europepmc   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch   +9 more
wiley   +1 more source

Cefdinir Versus Cephalexin for the Treatment of Uncomplicated Urinary Tract Infections. [PDF]

open access: yesOpen Forum Infect Dis
Mitzner TM   +4 more
europepmc   +1 more source

Innovative Drugs Approved in China After Registration Classification Reform: Current Status, Disparities, and Challenges

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Since 2016, the China National Medical Products Administration (NMPA) has reformed its drug registration classification rules and defines the innovative drugs as new drugs that have not been marketed domestically and overseas. This study sought to systematically evaluate the characteristics of the innovative drugs approved in China. The cross‐sectional
Xingyue Zhu, Die Xiao
wiley   +1 more source

Home - About - Disclaimer - Privacy